{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:58:45Z","timestamp":1792684725984,"version":"4.5.0"},"reference-count":283,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119092","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:44:00Z","timestamp":1782229440000},"page":"119092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Advances in respiratory syncytial virus therapeutics: A comprehensive review of small-molecule inhibitors, monoclonal antibodies, and vaccines"],"prefix":"10.1016","volume":"317","author":[{"given":"Guangqiang","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7460-2691","authenticated-orcid":false,"given":"Yong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119092_bib1","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1097\/CM9.0000000000003354","article-title":"Landscape of respiratory syncytial virus","volume":"137","author":"Duan","year":"2024","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.ejmech.2026.119092_bib2","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S1473-3099(18)30292-5","article-title":"The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates","volume":"18","author":"Mazur","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib3","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s11427-022-2250-0","article-title":"A human antibody potently neutralizes RSV by targeting the conserved hydrophobic region of prefusion F","volume":"66","author":"Yi","year":"2023","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.ejmech.2026.119092_bib4","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S1473-3099(22)00291-2","article-title":"Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape","volume":"23","author":"Mazur","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib5","first-page":"413","article-title":"Establishment of a new reverse genetics system for respiratory syncytial virus under the control of RNA polymerase II","volume":"67","author":"Takahashi","year":"2023","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.ejmech.2026.119092_bib6","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1093\/infdis\/jiac244","article-title":"All infants are at risk of developing medically attended respiratory syncytial virus lower respiratory tract infection and deserve protection","volume":"226","author":"Hodges","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib7","first-page":"12","article-title":"Respiratory syncytial virus vaccines: a review of the candidates and the approved vaccines","author":"Topalidou","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.ejmech.2026.119092_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/v10120716","article-title":"Human respiratory syncytial virus NS 1 targets TRIM25 to suppress RIG-I ubiquitination and subsequent RIG-I-Mediated antiviral signaling","volume":"10","author":"Ban","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.119092_bib9","first-page":"3","article-title":"Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease","volume":"372","author":"Collins","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.ejmech.2026.119092_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1146\/annurev-med-061323-073934","article-title":"New approaches to respiratory syncytial virus prevention and treatment","volume":"76","author":"Walter","year":"2025","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejmech.2026.119092_bib11","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/01.inf.0000108189.87181.7c","article-title":"Antigenic and genetic variation in human respiratory syncytial virus","volume":"23","author":"Wertz","year":"2004","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.ejmech.2026.119092_bib12","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1093\/infdis\/162.6.1283","article-title":"Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children","volume":"162","author":"Hall","year":"1990","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib13","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1517\/14712590903287499","article-title":"Motavizumab for the prevention of respiratory syncytial virus infection in infants","volume":"9","author":"Gill","year":"2009","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ejmech.2026.119092_bib14","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/INF.0000000000001150","article-title":"Association between updated guideline-based Palivizumab administration and hospitalizations for respiratory syncytial virus infections","volume":"35","author":"Grindeland","year":"2016","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.ejmech.2026.119092_bib15","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1086\/651603","article-title":"Pharmacologic advances in the treatment and prevention of respiratory syncytial virus","volume":"50","author":"Saravolatz","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000181.pub3","article-title":"Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children","author":"Ventre","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2026.119092_bib17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/d41586-023-01529-5","article-title":"\u2032A good day': FDA approves world's first RSV vaccine","volume":"617","author":"Vidal Valero","year":"2023","journal-title":"Nature (London, U. K.)"},{"key":"10.1016\/j.ejmech.2026.119092_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(23)00195-7","article-title":"First RSV vaccine approvals","volume":"4","author":"Venkatesan","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ejmech.2026.119092_bib19","first-page":"487","article-title":"FDA approves mRNA-based RSV vaccine","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119092_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/archdischild-2020-319472","article-title":"Palivizumab's real-world effectiveness: a population-based study in Ontario, Canada, 1993-2017","volume":"106","author":"Fitzpatrick","year":"2021","journal-title":"Arch. Dis. Child"},{"key":"10.1016\/j.ejmech.2026.119092_bib21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose Nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119092_bib22","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1097\/MS9.0000000000004792","article-title":"Clesrovimab approval for RSV: a lifesaving opportunity for global infant health equity","volume":"88","author":"Kumari","year":"2026","journal-title":"Ann. Med. Surgery"},{"key":"10.1016\/j.ejmech.2026.119092_bib23","first-page":"3","article-title":"Nirsevimab: a review, pediatr. Allergy","volume":"37","author":"Balbi","year":"2024","journal-title":"Immunol. Pulmonol."},{"key":"10.1016\/j.ejmech.2026.119092_bib24","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1128\/AAC.01497-15","article-title":"GS-5806 inhibits a broad range of respiratory syncytial virus clinical isolates by blocking the virus-cell fusion process","volume":"60","author":"Perron","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib25","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1093\/cid\/ciaa283","article-title":"Pharmacokinetics, safety, and antiviral effects of multiple doses of the Respiratory Syncytial Virus (RSV) fusion protein inhibitor, JNJ-53718678, in infants hospitalized with RSV infection: a randomized phase 1b study","volume":"71","author":"Martin\u00f3n-Torres","year":"2020","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.ejmech.2026.119092_bib26","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/infdis\/jiy227","article-title":"Antiviral activity of oral JNJ-53718678 in healthy adult volunteers challenged with respiratory syncytial virus: a placebo-controlled study","volume":"218","author":"Stevens","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib27","doi-asserted-by":"crossref","first-page":"38175","DOI":"10.1021\/acsomega.5c06080","article-title":"Development and optimization of a novel synthetic route for 2,4-Diamine-quinazoline containing ziresovir: a drug candidate for the treatment of Respiratory Syncytial Virus (RSV) infection","volume":"10","author":"You","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.119092_bib28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40121-020-00383-6","article-title":"The future of respiratory syncytial virus disease prevention and treatment","volume":"10","author":"Domachowske","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.ejmech.2026.119092_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13176","article-title":"Safety and efficacy of AK0529 in respiratory syncytial virus-infected infant patients: a phase 2 proof-of-concept trial","volume":"17","author":"Huang","year":"2023","journal-title":"Influenza and other respiratory viruses"},{"key":"10.1016\/j.ejmech.2026.119092_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01884-19","article-title":"A randomized, placebo-controlled, respiratory syncytial virus human challenge study of the antiviral efficacy, safety, and pharmacokinetics of RV521, an inhibitor of the RSV-F protein","volume":"64","author":"DeVincenzo","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/187152509789105471","article-title":"Respiratory syncytial virus (RSV) prevention and treatment: past, present, and future","volume":"7","author":"Weisman","year":"2009","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virs.2025.01.003","article-title":"Current antiviral therapies and promising drug candidates against respiratory syncytial virus infection","volume":"40","author":"Feng","year":"2025","journal-title":"Virol. Sin."},{"key":"10.1016\/j.ejmech.2026.119092_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0288271","article-title":"Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: safety, efficacy, and pharmacokinetic results","volume":"18","author":"Oey","year":"2023","journal-title":"PloS one"},{"key":"10.1016\/j.ejmech.2026.119092_bib34","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMoa1413275","article-title":"Activity of oral ALS-008176 in a respiratory syncytial virus challenge Study","volume":"373","author":"DeVincenzo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119092_bib35","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/infdis\/jiaa716","article-title":"Safety and antiviral effects of nebulized PC786 in a respiratory syncytial virus challenge Study","volume":"225","author":"DeVincenzo","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib36","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nchembio.1982","article-title":"Molecular mechanism of respiratory syncytial virus fusion inhibitors","volume":"12","author":"Battles","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119092_bib37","series-title":"Discovery and Development of Orally Active RSV Fusion Inhibitors","first-page":"353","author":"Meanwell","year":"2011"},{"key":"10.1016\/j.ejmech.2026.119092_bib38","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1128\/AAC.48.2.413-422.2004","article-title":"Orally active fusion inhibitor of respiratory syncytial virus","volume":"48","author":"Cianci","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib39","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1021\/acsmedchemlett.5b00008","article-title":"Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors","volume":"6","author":"Feng","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119092_bib40","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1039\/C9MD00178F","article-title":"Discovery of (aza)indole derivatives as novel respiratory syncytial virus fusion inhibitors","volume":"10","author":"Zheng","year":"2019","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2026.119092_bib41","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1021\/acsinfecdis.9b00524","article-title":"Accelerated discovery of potent fusion inhibitors for respiratory syncytial virus","volume":"6","author":"Pribut","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-00170-x","article-title":"Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor","volume":"8","author":"Roymans","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119092_bib43","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1021\/acs.jmedchem.0c01882","article-title":"Discovery of Sisunatovir (RV521), an inhibitor of respiratory syncytial virus fusion","volume":"64","author":"Cockerill","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib44","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.1021\/acs.jmedchem.0c00226","article-title":"A potent and orally bioavailable fusion inhibitor of respiratory syncytial virus","volume":"63","author":"Vendeville","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41467-017-00170-x","article-title":"Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor","volume":"8","author":"Roymans","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119092_bib46","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/acs.jmedchem.8b01361","article-title":"State of the art in respiratory syncytial virus drug Discovery and development","volume":"62","author":"Cockerill","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib47","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1021\/acsmedchemlett.7b00418","article-title":"Discovery of 3,3'-Spiro[Azetidine]-2-oxo-indoline derivatives as fusion inhibitors for treatment of RSV infection","volume":"9","author":"Shi","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119092_bib48","doi-asserted-by":"crossref","first-page":"10986","DOI":"10.1021\/acs.jmedchem.4c00514","article-title":"Spiro-Azetidine oxindoles as long-acting injectables for pre-exposure prophylaxis against respiratory syncytial virus infections","volume":"67","author":"Kesteleyn","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib49","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1021\/acs.jmedchem.0c01882","article-title":"Discovery of Sisunatovir (RV521), an inhibitor of respiratory syncytial virus fusion","volume":"64","author":"Cockerill","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib74","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1021\/acs.jmedchem.9b00654","article-title":"Discovery of Ziresovir as a potent, selective, and orally bioavailable respiratory syncytial virus fusion protein inhibitor","volume":"62","author":"Zheng","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib75","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1021\/jm5017768","article-title":"Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study","volume":"58","author":"Mackman","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib65","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01407-20","article-title":"Pharmacological characterization of TP0591816, a novel macrocyclic respiratory syncytial virus fusion inhibitor with antiviral activity against F protein mutants","volume":"65","author":"Yoshida","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib68","doi-asserted-by":"crossref","first-page":"18949","DOI":"10.1021\/acs.jmedchem.5c00692","article-title":"Discovery of tricyclic derivative as novel and potent respiratory syncytial virus fusion glycoprotein inhibitor with an improved pharmacokinetic profile","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib76","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/jm5017279","article-title":"Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection","volume":"58","author":"Wang","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib77","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1021\/acs.jmedchem.1c00071","article-title":"Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside leading to the discovery of Remdesivir (GS-5734) as a potent inhibitor of respiratory syncytial virus with efficacy in the African green monkey model of RSV","volume":"64","author":"Mackman","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib78","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00737-17","article-title":"Preclinical characterization of PC786, an inhaled small-molecule respiratory syncytial virus L protein polymerase inhibitor","volume":"61","author":"Coates","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib79","doi-asserted-by":"crossref","first-page":"13723","DOI":"10.1021\/acs.jmedchem.4c00525","article-title":"Discovery of gem-dimethyl-hydroxymethylpyridine derivatives as potent non-nucleoside RSV polymerase inhibitors","volume":"67","author":"Grosse","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib80","doi-asserted-by":"crossref","first-page":"16761","DOI":"10.1074\/jbc.RA118.004862","article-title":"Development of an allosteric inhibitor class blocking RNA elongation by the respiratory syncytial virus polymerase complex","volume":"293","author":"Cox","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib81","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01684-18","article-title":"Verdinexor (KPT-335), a selective inhibitor of nuclear export, reduces respiratory syncytial virus replication in vitro","volume":"93","author":"Jorquera","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2026.119092_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2025.1576669","article-title":"Pharmacokinetic evaluation and bioavailability of KPT-335 (Verdinexor) in cats","volume":"12","author":"Yang","year":"2025","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.ejmech.2026.119092_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009428","article-title":"EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model","volume":"17","author":"Rhodin","year":"2021","journal-title":"PLoS pathog."},{"key":"10.1016\/j.ejmech.2026.119092_bib84","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMoa2108903","article-title":"EDP-938, a respiratory syncytial virus inhibitor, in a human virus challenge","volume":"386","author":"Ahmad","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119092_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105734","article-title":"Mechanisms of antiviral activity of the new hDHODH inhibitor MEDS433 against respiratory syncytial virus replication","volume":"219","author":"Luganini","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2026.119092_bib86","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00608-20","article-title":"Inhibitory effect of PIK-24 on respiratory syncytial virus entry by blocking Phosphatidylinositol-3 kinase signaling","volume":"64","author":"Chen","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib50","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01884-19","article-title":"A randomized, Placebo-Controlled, respiratory syncytial virus human challenge study of the antiviral efficacy, safety, and pharmacokinetics of RV521, an inhibitor of the RSV-F protein","volume":"64","author":"DeVincenzo","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib51","doi-asserted-by":"crossref","first-page":"10228","DOI":"10.1021\/acs.jmedchem.8b01394","article-title":"Discovery of Benzoazepinequinoline (BAQ) derivatives as novel, potent, orally bioavailable respiratory syncytial virus fusion inhibitors","volume":"61","author":"Zheng","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib52","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1021\/acs.jmedchem.9b00654","article-title":"Discovery of Ziresovir as a potent, selective, and orally bioavailable respiratory syncytial virus fusion protein inhibitor","volume":"62","author":"Zheng","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib53","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2313551","article-title":"Ziresovir in hospitalized infants with respiratory syncytial virus infection","volume":"391","author":"Zhao","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119092_bib54","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1021\/jm5017768","article-title":"Discovery of an oral Respiratory Syncytial Virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge Study","volume":"58","author":"Mackman","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib55","doi-asserted-by":"crossref","first-page":"7109","DOI":"10.1128\/AAC.00761-15","article-title":"GS-5806 inhibits pre- to postfusion conformational changes of the respiratory syncytial virus fusion protein","volume":"59","author":"Samuel","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib56","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1128\/AAC.01497-15","article-title":"GS-5806 inhibits a broad range of respiratory syncytial virus clinical isolates by blocking the virus-cell fusion process","volume":"60","author":"Perron","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib57","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1401184","article-title":"Oral GS-5806 activity in a respiratory syncytial virus challenge study","volume":"371","author":"DeVincenzo","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119092_bib58","first-page":"64","article-title":"Assessment of drug resistance during phase 2b clinical trials of presatovir in adults naturally infected with respiratory syncytial virus","author":"Porter","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib59","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1128\/AAC.00487-15","article-title":"Antiviral efficacy of a Respiratory Syncytial Virus (RSV) fusion inhibitor in a bovine model of RSV infection","volume":"59","author":"Jordan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib60","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1401184","article-title":"Oral GS-5806 activity in a respiratory syncytial virus challenge study","volume":"371","author":"DeVincenzo","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119092_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.vetimm.2021.110323","article-title":"Neutrophil extracellular traps (NETs) in a randomized controlled trial of a combination of antiviral and nonsteroidal anti-inflammatory treatment in a bovine model of respiratory syncytial virus infection","volume":"241","author":"Mutua","year":"2021","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.ejmech.2026.119092_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230245","article-title":"A randomized controlled trial of a combination of antiviral and nonsteroidal anti-inflammatory treatment in a bovine model of respiratory syncytial virus infection","volume":"15","author":"Walsh","year":"2020","journal-title":"PloS one"},{"key":"10.1016\/j.ejmech.2026.119092_bib63","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/acsmedchemlett.0c00008","article-title":"Discovery of a potent dual inhibitor of wild-type and mutant respiratory syncytial virus fusion proteins","volume":"11","author":"Yamaguchi-Sasaki","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119092_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115818","article-title":"Discovery of a potent dual inhibitor of wild-type and mutant respiratory syncytial virus fusion proteins through the modulation of atropisomer interconversion properties","volume":"28","author":"Yamaguchi-Sasaki","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib66","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1248\/cpb.c19-00895","article-title":"Design and synthesis of 2-(1-Alkylaminoalkyl)pyrazolo 1,5-a pyrimidines as new respiratory syncytial virus fusion protein inhibitors","volume":"68","author":"Yamaguchi-Sasaki","year":"2020","journal-title":"Chem. Pharmaceut. Bull."},{"key":"10.1016\/j.ejmech.2026.119092_bib67","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41392-024-01858-5","article-title":"Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119092_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mbio.01385-24","article-title":"A new mechanism of respiratory syncytial virus entry inhibition by small-molecule to overcome K394R-associated resistance","volume":"15","author":"Song","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.ejmech.2026.119092_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2019.00247","article-title":"Dichloro-Phenyl-Benzotriazoles: a new selective class of human respiratory syncytial virus entry inhibitors","volume":"7","author":"Piras","year":"2019","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105547","article-title":"Identification and evaluation of a novel tribenzamide derivative as an inhibitor targeting the entry of the respiratory syncytial virus","volume":"211","author":"Issmail","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2026.119092_bib72","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1128\/AAC.48.2.413-422.2004","article-title":"Orally active fusion inhibitor of respiratory syncytial virus","volume":"48","author":"Cianci","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib73","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1016\/j.bmcl.2007.06.065","article-title":"Respiratory syncytial virus fusion inhibitors. Part 6: an examination of the effect of structural variation of the benzimidazol-2-one heterocycle moiety","volume":"17","author":"Combrink","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119092_bib87","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1590\/S1517-83822011000100043","article-title":"Structural analysis of human respiratory syncytial virus p protein: identification of intrinsically disordered domains","volume":"42","author":"Simabuco","year":"2011","journal-title":"Braz. J. Microbiol. [publication of the Brazilian Society for Microbiology]"},{"key":"10.1016\/j.ejmech.2026.119092_bib88","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.cell.2019.08.014","article-title":"Structure of the respiratory syncytial virus polymerase complex","volume":"179","author":"Gilman","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119092_bib89","article-title":"Cryo-EM structure of the respiratory syncytial virus RNA polymerase","volume":"11","author":"Cao","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119092_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004995","article-title":"Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2'-Fluoro-4'-Chloromethyl-Cytidine triphosphate","volume":"11","author":"Deval","year":"2015","journal-title":"PLoS pathog."},{"key":"10.1016\/j.ejmech.2026.119092_bib91","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119092_bib92","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib93","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","article-title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib94","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.molcel.2021.01.035","article-title":"Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication","volume":"81","author":"Bravo","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.119092_bib95","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1126\/science.abj5508","article-title":"4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication","volume":"375","author":"Sourimant","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119092_bib96","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-00963-7","article-title":"Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119092_bib97","first-page":"62","article-title":"Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses","author":"Yoon","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib98","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00178-25","article-title":"Discovery of a non-nucleoside inhibitor that binds to a novel site in the palm domain of the respiratory syncytial virus RNA-dependent RNA polymerase","volume":"99","author":"Kalin","year":"2025","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2026.119092_bib99","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1021\/acs.jmedchem.6b01568","article-title":"Identification of non-nucleoside inhibitors of the respiratory syncytial virus polymerase complex","volume":"60","author":"Jim\u00e9nez-Somarribas","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/aac.00800-24","article-title":"Structural basis of paramyxo- and pneumovirus polymerase inhibition by non-nucleoside small-molecule antivirals","volume":"68","author":"Wolf","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib101","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.antiviral.2004.12.002","article-title":"YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action","volume":"65","author":"Sudo","year":"2005","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2026.119092_bib102","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1128\/AAC.02540-14","article-title":"Characterization of a respiratory syncytial virus L protein inhibitor","volume":"58","author":"Tiong-Yip","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib103","doi-asserted-by":"crossref","first-page":"6789","DOI":"10.1016\/j.bmcl.2013.10.018","article-title":"Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor","volume":"23","author":"Xiong","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119092_bib104","doi-asserted-by":"crossref","first-page":"7786","DOI":"10.1128\/JVI.00530-15","article-title":"Respiratory syncytial virus inhibitor AZ-27 differentially inhibits different polymerase activities at the promoter","volume":"89","author":"Noton","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2026.119092_bib105","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1111\/bph.14221","article-title":"Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium","volume":"175","author":"Brookes","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119092_bib106","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.bmcl.2017.03.053","article-title":"Discovery of novel benzothienoazepine derivatives as potent inhibitors of respiratory syncytial virus","volume":"27","author":"Fordyce","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119092_bib107","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrd.2016.213","article-title":"DNA-encoded chemistry: enabling the deeper sampling of chemical space","volume":"16","author":"Goodnow","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119092_bib108","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/s42003-023-05451-4","article-title":"Structural and mechanistic insights into the inhibition of respiratory syncytial virus polymerase by a non-nucleoside inhibitor","volume":"6","author":"Yu","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejmech.2026.119092_bib109","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1021\/acsptsci.1c00118","article-title":"DNA-Encoded chemical libraries: a comprehensive review with successful stories and future challenges","volume":"4","author":"Gironda-Mart\u00ednez","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2026.119092_bib110","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1021\/acsmedchemlett.0c00615","article-title":"Trends in hit-to-lead optimization following DNA-Encoded library screens","volume":"12","author":"Reiher","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119092_bib111","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1021\/acs.jmedchem.4c02906","article-title":"DNA-Encoded library screen identifies novel series of respiratory syncytial virus polymerase inhibitors","volume":"68","author":"Carney","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib112","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1021\/acs.jmedchem.6b01568","article-title":"Identification of non-nucleoside inhibitors of the respiratory syncytial virus polymerase complex","volume":"60","author":"Jimenez-Somarribas","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib113","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo2236","article-title":"Orally efficacious lead of the AVG inhibitor series targeting a dynamic interface in the respiratory syncytial virus polymerase","volume":"8","author":"Sourimant","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2026.119092_bib114","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02576-20","article-title":"Discovery of a novel respiratory syncytial virus replication inhibitor","volume":"65","author":"Wang","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115136","article-title":"Insight into non-nucleoside triazole-based systems as viral polymerases inhibitors","volume":"249","author":"Bivacqua","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib116","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1093\/nar\/gkh809","article-title":"Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor","volume":"32","author":"Mason","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.119092_bib117","doi-asserted-by":"crossref","first-page":"13105","DOI":"10.1128\/JVI.79.20.13105-13115.2005","article-title":"Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase","volume":"79","author":"Liuzzi","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2026.119092_bib118","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.1128\/JVI.02374-08","article-title":"The respiratory syncytial virus matrix protein possesses a Crm1-mediated nuclear export mechanism","volume":"83","author":"Ghildyal","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2026.119092_bib119","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98767-2","article-title":"Reversible disruption of XPO1-mediated nuclear export inhibits respiratory syncytial virus (RSV) replication","volume":"11","author":"Mathew","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119092_bib120","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40121-018-0188-z","article-title":"Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children","volume":"7","author":"Sim\u00f5es","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.ejmech.2026.119092_bib121","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01684-18","article-title":"Verdinexor (KPT-335), a selective inhibitor of nuclear export, reduces respiratory syncytial virus replication in vitro","volume":"93","author":"Jorquera","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2026.119092_bib122","doi-asserted-by":"crossref","first-page":"26","DOI":"10.37201\/req\/096.2022","article-title":"EDP-938, a new antiviral with inhibitory activity against the nucleoprotein of the respiratory syncytial virus","volume":"36","author":"Reina","year":"2023","journal-title":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia"},{"key":"10.1016\/j.ejmech.2026.119092_bib123","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMoa2108903","article-title":"EDP-938, a respiratory syncytial virus inhibitor, in a human virus challenge","volume":"386","author":"Ahmad","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119092_bib124","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiae471","article-title":"EDP-938 has a high barrier to resistance in healthy adults experimentally infected with respiratory syncytial virus","volume":"231","author":"Levene","year":"2025","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib125","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1128\/AAC.04119-14","article-title":"Mechanism of action for respiratory syncytial virus inhibitor RSV604","volume":"59","author":"Challa","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib126","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejmech.2018.05.059","article-title":"Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR)","volume":"155","author":"Francesconi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115799","article-title":"Design, synthesis, and anti-respiratory syncytial virus potential of novel 3-(1,2,3-triazol-1-yl)furoxazine-fused benzimidazole derivatives","volume":"261","author":"Mao","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib128","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1021\/acs.jmedchem.9b00091","article-title":"Discovery, optimization, and target identification of novel potent broad-spectrum antiviral inhibitors","volume":"62","author":"Yang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib129","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0005-2760(98)00139-8","article-title":"Structure and function of phosphoinositide 3-kinases","volume":"1436","author":"Wymann","year":"1998","journal-title":"Biochimica et biophysica acta"},{"key":"10.1016\/j.ejmech.2026.119092_bib130","first-page":"130","volume":"vol. 42","author":"Hamada","year":"2019"},{"key":"10.1016\/j.ejmech.2026.119092_bib131","doi-asserted-by":"crossref","first-page":"41922","DOI":"10.1074\/jbc.M112.414789","article-title":"Transient activation of the PI3K-AKT pathway by hepatitis C virus to enhance viral entry","volume":"287","author":"Liu","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib132","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.bbrc.2015.01.126","article-title":"The involvement of FAK-PI3K-AKT-Rac1 pathway in porcine reproductive and respiratory syndrome virus entry","volume":"458","author":"Ni","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2026.119092_bib133","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000141","article-title":"Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus","volume":"4","author":"Saeed","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2026.119092_bib134","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00958-13","article-title":"Epidermal growth factor receptor-PI3K signaling controls cofilin activity to facilitate herpes simplex virus 1 entry into neuronal cells","volume":"5","author":"Zheng","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.ejmech.2026.119092_bib135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003309","article-title":"Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein","volume":"9","author":"Krzyzaniak","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2026.119092_bib136","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01453-22","article-title":"PIK-24 inhibits RSV-Induced syncytium Formation via direct interaction with the p85\u03b1 subunit of PI3K","volume":"96","author":"Chen","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2026.119092_bib137","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00608-20","article-title":"Inhibitory effect of PIK-24 on respiratory syncytial virus entry by blocking Phosphatidylinositol-3 kinase signaling","volume":"64","author":"Chen","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198277","article-title":"Repurposing of antiparasitic niclosamide to inhibit respiratory syncytial virus (RSV) replication","volume":"295","author":"Niyomdecha","year":"2021","journal-title":"Virus Res."},{"key":"10.1016\/j.ejmech.2026.119092_bib139","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.virol.2019.07.002","article-title":"High-throughput screening of active compounds against human respiratory syncytial virus","volume":"535","author":"Fu","year":"2019","journal-title":"Virology"},{"key":"10.1016\/j.ejmech.2026.119092_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104817","article-title":"Imiquimod suppresses respiratory syncytial virus (RSV) replication via PKA pathway and reduces RSV induced-inflammation and viral load in mice lungs","volume":"179","author":"Salinas","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2026.119092_bib141","doi-asserted-by":"crossref","first-page":"12945","DOI":"10.1021\/acs.jmedchem.4c00899","article-title":"Discovery of GS-7682, a novel 4'-Cyano-Modified C-Nucleoside prodrug with broad activity against Pneumo- and picornaviruses and efficacy in RSV-Infected African Green Monkeys","volume":"67","author":"Siegel","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117282","article-title":"Unlocking the antiviral arsenal: Structure-guided optimization of small-molecule inhibitors against RSV and hCoV-229E","volume":"291","author":"Karhan","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib143","doi-asserted-by":"crossref","DOI":"10.3390\/v15122300","article-title":"Antiviral potential of azelastine against major respiratory viruses","volume":"15","author":"Fischhuber","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.119092_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105518","article-title":"Design and synthesis of a new series of hybrids of functionalised N(1)-[(1H-1,2,3-triazol-4-yl)methyl]quinazoline-2,4-dione with antiviral activity against Respiratory Syncytial Virus","volume":"209","author":"G\u0142owacka","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2026.119092_bib145","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1039\/C8MD00033F","article-title":"Conformationally restricted benzothienoazepine respiratory syncytial virus inhibitors: their synthesis, structural analysis and biological activities","volume":"9","author":"Fordyce","year":"2018","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2026.119092_bib146","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.1058229","article-title":"Synthesis and evaluation of 3-alkynyl-5-aryl-7-aza-indoles as broad-spectrum antiviral agents","volume":"10","author":"Martinez-Gualda","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib147","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914540","article-title":"Phenotypic Test of Benzo 4,5 imidazo 1,2-c pyrimidinone-based Nucleoside and Non-Nucleoside Derivatives against DNA and RNA viruses, including coronaviruses","volume":"24","author":"Kamzeeva","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119092_bib148","doi-asserted-by":"crossref","DOI":"10.3390\/v17070890","article-title":"Broad-Spectrum antiviral activity of pyridobenzothiazolone analogues against respiratory viruses","volume":"17","author":"Feyles","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.119092_bib149","doi-asserted-by":"crossref","DOI":"10.3390\/v15040989","article-title":"The flavonoid cyanidin shows immunomodulatory and broad-spectrum antiviral properties, including SARS-CoV-2","volume":"15","author":"Vicente","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.119092_bib150","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12985-020-01451-6","article-title":"Luteolin inhibits respiratory syncytial virus replication by regulating the MiR-155\/SOCS1\/STAT1 signaling pathway","volume":"17","author":"Wang","year":"2020","journal-title":"Virol. J."},{"key":"10.1016\/j.ejmech.2026.119092_bib151","article-title":"Elimination of gut microbiota hinders the therapeutic effect of amentoflavone on respiratory syncytial virus-induced lung inflammation injury by regulating innate immunity","volume":"145","author":"Sun","year":"2025","journal-title":"Phytomed. Int. J. Phytother. Phytopharmacol."},{"key":"10.1016\/j.ejmech.2026.119092_bib152","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1021\/acs.jnatprod.2c01007","article-title":"Crotofolane diterpenoids and other constituents isolated from Croton kilwae","volume":"86","author":"Mahambo","year":"2023","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2026.119092_bib153","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1021\/acs.jnatprod.3c01288","article-title":"Antiviral Rotenoids and Isoflavones isolated from Millettia oblata ssp. teitensis","volume":"87","author":"Kiganda","year":"2024","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2026.119092_bib154","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1393511","article-title":"Emodin inhibits respiratory syncytial virus entry by interactions with fusion protein","volume":"15","author":"Xiong","year":"2024","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejmech.2026.119092_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.106007","article-title":"Modulating apoptosis as a novel therapeutic strategy against Respiratory Syncytial Virus infection: insights from Rotenone","volume":"231","author":"Zhang","year":"2024","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2026.119092_bib156","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1021\/acs.jnatprod.3c01143","article-title":"Absolute configuration of oxabornyl polyenes prugosenes A1-A3 and structural revision of prugosene A2","volume":"87","author":"Lin","year":"2024","journal-title":"J Nat. Prod."},{"key":"10.1016\/j.ejmech.2026.119092_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.fitote.2021.105055","article-title":"Antiviral iridoid glycosides from Clerodendrum myricoides","volume":"155","author":"Umereweneza","year":"2021","journal-title":"Fitoterapia"},{"key":"10.1016\/j.ejmech.2026.119092_bib158","doi-asserted-by":"crossref","first-page":"17067","DOI":"10.1016\/S0021-9258(19)47340-7","article-title":"Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps","volume":"266","author":"Lytton","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib159","doi-asserted-by":"crossref","DOI":"10.3390\/v12101093","article-title":"Thapsigargin at non-cytotoxic levels induces a potent host antiviral response that blocks influenza A virus replication","volume":"12","author":"Goulding","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.119092_bib160","doi-asserted-by":"crossref","DOI":"10.3390\/v13020234","article-title":"Thapsigargin is a broad-spectrum inhibitor of major human respiratory viruses: Coronavirus, respiratory syncytial virus and influenza A virus","volume":"13","author":"Al-Beltagi","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.119092_bib161","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.fitote.2018.08.018","article-title":"Terpenoids from the stems of Celastrus hindsii and their anti-RSV activities","volume":"130","author":"Luo","year":"2018","journal-title":"Fitoterapia"},{"key":"10.1016\/j.ejmech.2026.119092_bib162","article-title":"Anti-inflammatory and antiviral activities of compounds from the fruit of Pouteria caimito","volume":"10","author":"Zhao","year":"2024","journal-title":"Cogent Food Agric."},{"key":"10.1016\/j.ejmech.2026.119092_bib163","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jep.2013.04.040","article-title":"Water extract of licorice had anti-viral activity against human respiratory syncytial virus in human respiratory tract cell lines","volume":"148","author":"Feng Yeh","year":"2013","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2026.119092_bib164","doi-asserted-by":"crossref","DOI":"10.3390\/md22120551","article-title":"New sesterterpenes from the antarctic sponge suberites sp","volume":"22","author":"Olsen","year":"2024","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejmech.2026.119092_bib165","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jsbmb.2008.05.005","article-title":"Anti-herpetic and anti-inflammatory activities of two new synthetic 22,23-dihydroxylated stigmastane derivatives","volume":"111","author":"Michelini","year":"2008","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.119092_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104879","article-title":"A synthetic stigmastane displays antiadenoviral activity and reduces the inflammatory response to viral infection","volume":"183","author":"Michelini","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2026.119092_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e20148","article-title":"Two synthetic steroid analogs reduce human respiratory syncytial virus replication and the immune response to infection both in vitro and in vivo","volume":"9","author":"Bueno","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.ejmech.2026.119092_bib168","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1039\/D4QO00520A","article-title":"Xanthrysols A\u2013D, novel meroterpenoids with antiviral activities from Xanthostemon chrysanthus","volume":"11","author":"Liu","year":"2024","journal-title":"Org. Chem. Front."},{"key":"10.1016\/j.ejmech.2026.119092_bib169","article-title":"Xanthochrysanthones A-C, novel lobster-shape cinnamoyltriketone dimers with antiviral activities from Xanthostemon chrysanthus","volume":"31","author":"Zhan","year":"2025","journal-title":"Chem. (Weinheim an der Bergstrasse, Germany)"},{"key":"10.1016\/j.ejmech.2026.119092_bib170","article-title":"Evaluation of the therapeutic potential of traditionally-used natural plant extracts to inhibit proliferation of a HeLa cell cancer line and replication of human respiratory syncytial virus (hRSV)","volume":"13","author":"Brill","year":"2024","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.ejmech.2026.119092_bib171","doi-asserted-by":"crossref","first-page":"8230","DOI":"10.1038\/s41598-024-58032-8","article-title":"Ginkgolic acid inhibits orthopneumo- and metapneumo- virus infectivity","volume":"14","author":"Luck","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119092_bib172","first-page":"972","article-title":"Structurally novel tryptamine-derived alkaloids from the seeds of Peganum harmala and their antiviral activities against respiratory syncytial virus","volume":"23","author":"Wu","year":"2025","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.ejmech.2026.119092_bib173","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/10286020.2023.2288290","article-title":"Tautomeric cinnamoylphloroglucinol-monoterpene adducts from Cleistocalyx operculatus and their antiviral activities","volume":"26","author":"Song","year":"2024","journal-title":"J. Asian Nat. Prod. Res."},{"key":"10.1016\/j.ejmech.2026.119092_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106458","article-title":"Hypoglycemic oligostilbenes from the stems of Caragana sinica","volume":"134","author":"Sun","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib175","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01536-24","article-title":"Both chebulagic acid and punicalagin inhibit respiratory syncytial virus entry via multi-targeting glycoprotein and fusion protein","volume":"98","author":"Xiong","year":"2024","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2026.119092_bib176","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612933","article-title":"Identification and Study of the action mechanism of small compound that inhibits replication of respiratory syncytial virus","volume":"24","author":"Shtro","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119092_bib177","first-page":"26","article-title":"Monoterpene-containing substituted coumarins as inhibitors of respiratory Syncytial Virus (RSV) replication","author":"Khomenko","year":"2021","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/j.ejmech.2026.119092_bib178","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1039\/D4MD00728J","article-title":"Design, synthesis and antiviral evaluation of triazole-linked 7-hydroxycoumarin-monoterpene conjugates as inhibitors of RSV replication","volume":"16","author":"Tsypyshev","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib179","first-page":"28","article-title":"New inhibitors of Respiratory Syncytial Virus (RSV) replication based on monoterpene-substituted arylcoumarins","author":"Khomenko","year":"2023","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/j.ejmech.2026.119092_bib180","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1038\/s41598-023-35272-8","article-title":"Integrating metabolomics and network pharmacology to assess the effects of quercetin on lung inflammatory injury induced by human respiratory syncytial virus","volume":"13","author":"Sun","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119092_bib181","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijbiomac.2017.12.141","article-title":"Binding investigation between M2-1protein from hRSV and acetylated quercetin derivatives: (1)H NMR, fluorescence spectroscopy, and molecular docking","volume":"111","author":"Guimar\u00e3es","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2026.119092_bib182","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00044-024-03204-4","article-title":"Diffractaic acid and its ethers as anti-respiratory syncytial virus agents","volume":"33","author":"Filimonov","year":"2024","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2026.119092_bib183","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3762\/bjoc.18.161","article-title":"New triazole-substituted triterpene derivatives exhibiting anti-RSV activity: synthesis, biological evaluation, and molecular modeling","volume":"18","author":"da Silva","year":"2022","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib184","doi-asserted-by":"crossref","first-page":"134","DOI":"10.37201\/req\/147.2023","article-title":"Respiratory syncytial virus: a new era","volume":"37","author":"Ruiz-Galiana","year":"2024","journal-title":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia"},{"key":"10.1016\/j.ejmech.2026.119092_bib185","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/jac\/dkad076","article-title":"Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants","volume":"78","author":"Jorgensen","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib186","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.3389\/fimmu.2019.02778","article-title":"Antibody epitopes of pneumovirus fusion proteins","volume":"10","author":"Huang","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119092_bib187","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.7150\/ijbs.64762","article-title":"Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies","volume":"17","author":"Shang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejmech.2026.119092_bib188","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.3928\/19382359-20180816-01","article-title":"Preventing pediatric respiratory syncytial virus infection","volume":"47","author":"Domachowske","year":"2018","journal-title":"Pediatr Ann"},{"key":"10.1016\/j.ejmech.2026.119092_bib189","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01714-16","article-title":"Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults, Antimicrob","volume":"61","author":"Griffin","year":"2017","journal-title":"Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib190","doi-asserted-by":"crossref","first-page":"e4400","DOI":"10.1093\/cid\/ciaa951","article-title":"Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants","volume":"73","author":"Sim\u00f5es","year":"2021","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.ejmech.2026.119092_bib191","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S2213-2600(20)30320-9","article-title":"Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Cunningham","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejmech.2026.119092_bib192","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2576","article-title":"Systematic review of the efficacy and safety of RSV-Specific monoclonal antibodies and antivirals in development","volume":"34","author":"Sevendal","year":"2024","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.ejmech.2026.119092_bib193","article-title":"Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state","volume":"8","author":"Rossey","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119092_bib194","article-title":"Monoclonal Antibody against G glycoprotein increases respiratory syncytial virus clearance in vivo and prevents vaccine- enhanced diseases","volume":"12","author":"Lee","year":"2017","journal-title":"PloS one"},{"key":"10.1016\/j.ejmech.2026.119092_bib195","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1186\/s12879-024-10120-w","article-title":"RSM01, a novel respiratory syncytial virus monoclonal antibody: preclinical characterization and results of a first-in-human, randomised clinical trial","volume":"24","author":"Bonavia","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib196","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.tim.2017.09.009","article-title":"Clinical potential of prefusion RSV F-specific antibodies","volume":"26","author":"Rossey","year":"2018","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.ejmech.2026.119092_bib197","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.virusres.2011.09.020","article-title":"Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years","volume":"162","author":"Collins","year":"2011","journal-title":"Virus Res."},{"key":"10.1016\/j.ejmech.2026.119092_bib198","doi-asserted-by":"crossref","DOI":"10.3390\/v15101999","article-title":"Host responses to respiratory syncytial virus infection","volume":"15","author":"Agac","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.119092_bib199","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1542\/peds.102.5.1211","article-title":"Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejmech.2026.119092_bib200","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"A humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group","volume":"102","author":"Palivizumab","year":"1998","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejmech.2026.119092_bib201","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.708939","article-title":"Coadministration of anti-viral monoclonal antibodies with routine pediatric vaccines and implications for nirsevimab use: a white paper","volume":"12","author":"Esposito","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119092_bib202","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119092_bib203","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1283120","article-title":"Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection","volume":"14","author":"Brady","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.ejmech.2026.119092_bib204","first-page":"1","article-title":"Development and comparison of three cell-based potency assays for anti-respiratory syncytial virus monoclonal antibody","volume":"74","author":"Sun","year":"2021","journal-title":"Biol. J. Int. Assoc. Biol. Stand."},{"key":"10.1016\/j.ejmech.2026.119092_bib205","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/INF.0000000000001916","article-title":"Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants","volume":"37","author":"Domachowske","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.ejmech.2026.119092_bib206","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/AAC.01285-13","article-title":"A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults, Antimicrob","volume":"57","author":"Robbie","year":"2013","journal-title":"Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib207","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40265-022-01829-6","article-title":"Nirsevimab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119092_bib208","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/cpdd.883","article-title":"A phase 1 randomized, Double-blind, placebo-controlled trial to assess the safety, tolerability, and pharmacokinetics of a respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy adults","volume":"10","author":"Aliprantis","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ejmech.2026.119092_bib209","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa2502984","article-title":"Clesrovimab for prevention of RSV disease in healthy infants","volume":"393","author":"Zar","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119092_bib210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103651","article-title":"Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis","volume":"73","author":"Maas","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejmech.2026.119092_bib211","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jmb.2007.02.024","article-title":"Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract","volume":"368","author":"Wu","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.119092_bib212","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1128\/AAC.01802-15","article-title":"Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection","volume":"60","author":"Detalle","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib213","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1086\/600108","article-title":"Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB\/c mice","volume":"200","author":"Haynes","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib214","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.antiviral.2018.04.014","article-title":"Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB\/c mouse model","volume":"154","author":"Caidi","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2026.119092_bib215","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s11095-023-03520-1","article-title":"Recent advances in inhaled nanoformulations of vaccines and therapeutics targeting respiratory viral infections","volume":"40","author":"Loo","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejmech.2026.119092_bib216","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00485-21","article-title":"Potent human single-domain antibodies specific for a novel prefusion epitope of respiratory syncytial virus F glycoprotein","volume":"95","author":"Xun","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2026.119092_bib217","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/cts.13290","article-title":"A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK -1654 in healthy Japanese adults","volume":"15","author":"Orito","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ejmech.2026.119092_bib218","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.1093\/infdis\/jiae581","article-title":"A phase 1b\/2a trial of a half-life extended respiratory syncytial virus neutralizing antibody, Clesrovimab, in healthy preterm and full-term infants","volume":"231","author":"Madhi","year":"2025","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib219","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiae582","article-title":"Development of high-titer Antidrug antibodies in a phase 1b\/2a infant clesrovimab trial are associated with RSV exposure beyond day 150","volume":"231","author":"Thambi","year":"2025","journal-title":"J. Infect. Dis."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2026.119092_bib220","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jped.2022.10.004","article-title":"Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood","volume":"99","author":"Scotta","year":"2023","journal-title":"J. Pediatr. (Rio J)"},{"key":"10.1016\/j.ejmech.2026.119092_bib221","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115851","article-title":"Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults","volume":"169","author":"Phuah","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.119092_bib222","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.880368","article-title":"RSV prevention in all infants: which is the most preferable strategy","volume":"13","author":"Esposito","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119092_bib223","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1186\/s12879-024-10196-4","article-title":"Replacing serum with dried blood microsampling for pharmacokinetics, viral neutralisation and immunogenicity bioanalysis supporting future paediatric development of RSM01, a candidate respiratory syncytial virus neutralising monoclonal antibody","volume":"24","author":"White","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib224","doi-asserted-by":"crossref","DOI":"10.1038\/srep34108","article-title":"Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus","volume":"6","author":"Killikelly","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119092_bib225","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science (Washington, DC, U. S.)"},{"key":"10.1016\/j.ejmech.2026.119092_bib226","doi-asserted-by":"crossref","first-page":"696","DOI":"10.15585\/mmwr.mm7332e1","article-title":"Use of respiratory syncytial virus vaccines in adults aged \u226560 years: updated recommendations of the advisory committee on immunization practices - united States","volume":"73","author":"Britton","year":"2024","journal-title":"2024, Morb. Mortal. Wkly. Rep"},{"key":"10.1016\/j.ejmech.2026.119092_bib227","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/d41573-023-00085-x","article-title":"RSV vaccines score landmark FDA approvals","volume":"22","author":"Kingwell","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119092_bib228","first-page":"1053","article-title":"Bivalent prefusion F Vaccine in pregnancy to prevent RSV illness in infants","volume":"389","author":"Buonsenso","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119092_bib229","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119092_bib230","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1016\/j.vaccine.2024.03.070","article-title":"Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: results of a randomized phase 3 study","volume":"42","author":"Baker","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2026.119092_bib231","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-Based RSV PreF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119092_bib232","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/infdis\/jiz603","article-title":"Live respiratory syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children","volume":"221","author":"McFarland","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib233","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/infdis\/jiz408","article-title":"Safety and immunogenicity of the respiratory syncytial virus vaccine RSV\/DeltaNS2\/Delta1313\/I1314L in RSV-seronegative children","volume":"222","author":"Karron","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib234","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/infdis\/jiad281","article-title":"Evaluation of the live-attenuated intranasal Respiratory Syncytial Virus (RSV) vaccine RSV\/6120\/\u0394NS2\/1030s in RSV-seronegative young children","volume":"229","author":"Karron","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib235","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1093\/infdis\/jiaa049","article-title":"Live-attenuated respiratory syncytial virus vaccine with M2-2 deletion and with small hydrophobic noncoding region is highly immunogenic in children","volume":"221","author":"McFarland","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib236","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/14760584.2019.1675520","article-title":"Vaccines against human respiratory syncytial virus in clinical trials, where are we now?","volume":"18","author":"Rossey","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ejmech.2026.119092_bib237","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.resinv.2022.11.003","article-title":"Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: a phase I, randomized, observer-blind clinical trial","volume":"61","author":"Kotb","year":"2023","journal-title":"Respir. Invest."},{"key":"10.1016\/j.ejmech.2026.119092_bib238","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/infdis\/jiy177","article-title":"A respiratory syncytial virus vaccine based on the small hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study","volume":"218","author":"Langley","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib239","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1080\/21645515.2020.1779517","article-title":"Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults","volume":"17","author":"Scaggs Huang","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.ejmech.2026.119092_bib240","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/infdis\/jiad271","article-title":"Safety and immunogenicity of a ChAd155-Vectored respiratory syncytial Virus vaccine in infants 6-7 months of age: a phase 1\/2 randomized trial","volume":"229","author":"S\u00e1ez-Llorens","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib241","doi-asserted-by":"crossref","first-page":"6088","DOI":"10.1016\/j.vaccine.2020.07.029","article-title":"First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial","volume":"38","author":"Verdijk","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2026.119092_bib242","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/infdis\/jiz408","article-title":"Safety and immunogenicity of the respiratory syncytial Virus vaccine RSV\/\u0394NS2\/\u03941313\/I1314L in RSV-Seronegative children","volume":"222","author":"Karron","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib243","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1093\/infdis\/jiac253","article-title":"Evaluation of recombinant live-attenuated Respiratory Syncytial Virus (RSV) vaccines RSV\/\u0394NS2\/\u03941313\/I1314L and RSV\/276 in RSV-Seronegative children","volume":"226","author":"Cunningham","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119092_bib244","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2557676","article-title":"Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12-59 months","volume":"21","author":"Schnyder Ghamloush","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ejmech.2026.119092_bib245","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1080\/21645515.2020.1829899","article-title":"A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults","volume":"17","author":"Aliprantis","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ejmech.2026.119092_bib246","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.ejmech.2026.119092_bib247","doi-asserted-by":"crossref","first-page":"7805","DOI":"10.1038\/s41467-025-63084-z","article-title":"Highly scalable prefusion-stabilized RSV F vaccine with enhanced immunogenicity and robust protection","volume":"16","author":"Huang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119092_bib248","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms14051130","article-title":"Structural advances in respiratory syncytial virus: implications for vaccine and antiviral development","volume":"14","author":"Huang","year":"2026","journal-title":"Microorganisms"},{"key":"10.1016\/j.ejmech.2026.119092_bib249","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.ejmech.2026.119092_bib250","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nsmb.3267","article-title":"Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV","volume":"23","author":"Joyce","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.119092_bib251","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128779","article-title":"A cysteine zipper stabilizes a pre-fusion F Glycoprotein vaccine for respiratory syncytial virus","volume":"10","author":"Stewart-Jones","year":"2015","journal-title":"PloS one"},{"key":"10.1016\/j.ejmech.2026.119092_bib252","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1038\/s41564-024-01860-1","article-title":"A foldon-free prefusion F trimer vaccine for respiratory syncytial virus to reduce off-target immune responses","volume":"9","author":"Bakkers","year":"2024","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejmech.2026.119092_bib253","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00087-25","article-title":"Hydrophobic residue substitutions enhance the stability and in vivo immunogenicity of respiratory syncytial virus fusion protein","volume":"99","author":"Song","year":"2025","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2026.119092_bib254","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN\u03b3 response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ejmech.2026.119092_bib255","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev. Vaccine"},{"key":"10.1016\/j.ejmech.2026.119092_bib256","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the Herpes Zoster Subunit Vaccine in adults 70 years of Age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119092_bib257","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S2213-2600(25)00048-7","volume":"13","author":"Ison","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejmech.2026.119092_bib258","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1624007","article-title":"Evaluating the efficacy, safety, and immunogenicity of FDA-approved RSV vaccines: a systematic review of Arexvy, Abrysvo, and mResvia","volume":"16","author":"Alandijany","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119092_bib259","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/AOG.0000000000005816","article-title":"Efficacy, safety, and immunogenicity of the MATISSE (maternal immunization Study for safety and efficacy) maternal respiratory syncytial virus prefusion F protein vaccine trial","volume":"145","author":"Sim\u00f5es","year":"2025","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ejmech.2026.119092_bib260","volume":"vol. 13","author":"Zhou","year":"2024"},{"key":"10.1016\/j.ejmech.2026.119092_bib261","doi-asserted-by":"crossref","first-page":"579","DOI":"10.5694\/mja2.52671","article-title":"Respiratory syncytial virus preventives for children in Australia: current landscape and future directions","volume":"222","author":"Barnett","year":"2025","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.ejmech.2026.119092_bib262","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.coviro.2017.03.012","article-title":"Vaccine development for respiratory syncytial virus","volume":"23","author":"Graham","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ejmech.2026.119092_bib263","doi-asserted-by":"crossref","first-page":"e680","DOI":"10.1093\/cid\/ciaf061","article-title":"Efficacy, immunogenicity, and safety of the bivalent Respiratory Syncytial Virus (RSV) prefusion F Vaccine in older adults over 2 RSV seasons","volume":"81","author":"Walsh","year":"2026","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.ejmech.2026.119092_bib264","volume":"vol. 14","author":"Cheah","year":"2026"},{"key":"10.1016\/j.ejmech.2026.119092_bib265","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.44756","article-title":"Burden of Respiratory Syncytial Virus-Associated Hospitalizations in US Adults, October 2016 to September 2023","volume":"7","author":"Havers","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ejmech.2026.119092_bib266","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/ni.2588","article-title":"Understanding immunosenescence to improve responses to vaccines","volume":"14","author":"Goronzy","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2026.119092_bib267","doi-asserted-by":"crossref","first-page":"e708","DOI":"10.1093\/cid\/ciaf292","article-title":"Safety, tolerability, and immunogenicity of mRNA-1345 in adults at increased risk for respiratory syncytial virus disease aged 18-59 years","volume":"81","author":"Mayer","year":"2026","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.ejmech.2026.119092_bib268","doi-asserted-by":"crossref","first-page":"696","DOI":"10.15585\/mmwr.mm7332e1","article-title":"Use of respiratory syncytial virus vaccines in adults aged \u226560 years: updated Recommendations of the Advisory Committee on immunization practices - united States, 2024","volume":"73","author":"Britton","year":"2024","journal-title":"MMWR. Moribidity Mortal. Wkly. Rep."},{"key":"10.1016\/j.ejmech.2026.119092_bib269","doi-asserted-by":"crossref","first-page":"e855","DOI":"10.1093\/cid\/ciaf515","article-title":"Immunogenicity of revaccination with mRNA-1345, an mRNA vaccine against respiratory syncytial virus, administered 12 months following a primary dose in adults aged \u226550 years","volume":"82","author":"Goswami","year":"2026","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.ejmech.2026.119092_bib270","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(24)01738-0","article-title":"Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis","volume":"404","author":"Payne","year":"2024","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejmech.2026.119092_bib271","doi-asserted-by":"crossref","first-page":"e1112","DOI":"10.1093\/cid\/ciag108","article-title":"Respiratory syncytial virus vaccination in solid organ transplant recipients: interim findings from a phase 3 trial of mRNA-1345","volume":"82","author":"Mayer","year":"2026","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.ejmech.2026.119092_bib272","doi-asserted-by":"crossref","DOI":"10.3390\/v17060793","article-title":"Insights into the currently available drugs and investigational compounds against RSV with a focus on their drug-resistance profiles","volume":"17","author":"Magnapera","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.119092_bib273","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01205-21","article-title":"Mechanism of cross-resistance to fusion inhibitors conferred by the K394R mutation in respiratory syncytial virus fusion protein","volume":"95","author":"Tang","year":"2021","journal-title":"J. Virol"},{"key":"10.1016\/j.ejmech.2026.119092_bib274","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02576-20","article-title":"Discovery of a novel respiratory syncytial virus replication inhibitor","volume":"65","author":"Wang","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119092_bib275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154097","article-title":"Biochemical effect of resistance mutations against synergistic inhibitors of RSV RNA polymerase","volume":"11","author":"Deval","year":"2016","journal-title":"PloS one"},{"key":"10.1016\/j.ejmech.2026.119092_bib276","doi-asserted-by":"crossref","first-page":"11543","DOI":"10.1021\/acs.jmedchem.4c00630","article-title":"Recent progress toward the discovery of small molecules as novel anti-respiratory syncytial virus agents","volume":"67","author":"Felicetti","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119092_bib277","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-020-01378-w","article-title":"Remdesivir: first approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119092_bib278","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1080\/07391102.2024.2308780","article-title":"Aspirin as a potential drug repurposing candidate targeting estrogen receptor alpha in breast cancer: a molecular dynamics and in-vitro study","volume":"43","author":"Kaur","year":"2025","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejmech.2026.119092_bib279","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12967-016-1031-5","article-title":"Repurposing of approved cardiovascular drugs","volume":"14","author":"Ishida","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119092_bib280","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug repurposing: a promising tool to accelerate the drug discovery process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119092_bib281","doi-asserted-by":"crossref","first-page":"22213","DOI":"10.1021\/acsomega.4c01207","article-title":"Structure-Based discovery of allosteric inhibitors targeting a new druggable site in the respiratory syncytial virus polymerase","volume":"9","author":"Oraby","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.119092_bib282","doi-asserted-by":"crossref","first-page":"7627","DOI":"10.1038\/s41467-023-43434-5","article-title":"Structure of the N-RNA\/P interface indicates mode of L\/P recruitment to the nucleocapsid of human metapneumovirus","volume":"14","author":"Whitehead","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119092_bib283","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1743-422X-3-34","article-title":"Contribution of cysteine residues in the extracellular domain of the F protein of human respiratory syncytial virus to its function","volume":"3","author":"Day","year":"2006","journal-title":"Virol. J."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:59:36Z","timestamp":1787039976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426005374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":283,"alternative-id":["S0223523426005374"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119092","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in respiratory syncytial virus therapeutics: A comprehensive review of small-molecule inhibitors, monoclonal antibodies, and vaccines","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119092"}}